Levetiracetam in Central Pain in Multiple Sclerosis(MS)

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• ms diagnosis verified

• age > 18 years

• central pain symptoms for more than 3 months

• central pain diagnosis confirmed by neurological examination

• adequate anticonceptive treatment for women with child bearing potential

• informed consent

• baseline pain of more than 4 on numeric rating scale

Exclusion Criteria:

• other cause of pain

• previous allergic reaction towards levetiracetam

• known adverse drug reaction on levetiracetam

• pregnancy

• severe disease

• inability to follow study protocol

• treatment with antidepressants, other anticonvulsants or opioids